Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Persistent or Recurrent Rare Epithelial Ovarian TumorsRET fusion−positivemetastatic Non-Small Cell Lung Cancer

Phase 2

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruitingCTIS2023-508194-89-00

F. Hoffmann-La Roche AGPersistent or Recurrent Rare Epithelial Ovarian Tumors

Start: 2021-08-30Target: 57Updated: 2026-01-06

Phase 3

A Phase III, Randomized, Open-Label Study of Pralsetinib versus Standard Of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

CompletedCTIS2023-505035-12-00

F. Hoffmann-La Roche AGmetastatic Non-Small Cell Lung Cancer, RET fusion−positive

Start: 2020-06-12End: 2025-01-27Target: 140Updated: 2025-03-03